Основная статистика
| LEI | 529900PWLRCA840VVK89 |
| CIK | 749647 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Imunon Inc
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 IMUNON, INC. |
|
| August 28, 2025 |
IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement Exhibit 99.1 IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement LAWRENCEVILLE, N.J., August 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasda |
|
| August 5, 2025 |
Exhibit 99.1 IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call tod |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In |
|
| August 5, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Imunon, Inc. |
|
| July 28, 2025 |
Exhibit 99.1 IMUNON Announces Stock Dividend Boosting Shareholder Value Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Di |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Imunon, Inc. |
|
| July 23, 2025 |
IMUNON Announces Reverse Stock Split Exhibit 99.1 IMUNON Announces Reverse Stock Split LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every fifteen (15) shares o |
|
| July 23, 2025 |
Amendment to the Restated Certificate of Incorporation, dated July 21, 2025 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. Imunon, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Imunon, Inc. SECOND: This Certificate of Amendment (the “Certificate of Amendment”) amends the pro |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 Imunon, Inc. |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 IMUNON, INC. |
|
| July 22, 2025 |
IMUNON, INC. Up to $10,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated May 22, 2024 and Prospectus Supplement dated September 3, 2024) IMUNON, INC. Up to $10,000,000 of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated September 3, 2024 (the “ATM Prospectus Supplement”), to the accompanying base |
|
| July 14, 2025 |
IMUNON, Inc. 2018 Stock Incentive Plan, as amended as of July 11, 2025 EXHIBIT 10.1 IMUNON, INC. THE 2018 STOCK INCENTIVE PLAN AS AMENDED AS OF JULY 11, 2025 I. INTRODUCTION 1.1 Purposes. The purposes of the IMUNON, INC. 2018 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to a |
|
| July 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 IMUNON, INC. |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 Imunon, Inc. |
|
| July 11, 2025 |
Amendment to the Restated Certificate of Incorporation, dated July 11, 2025 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. Imunon, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of the Corporation is Imunon, Inc. SECOND: This Certificate of Amendment (the “Certificate of Amendment”) amends the pro |
|
| June 13, 2025 |
IMUNON, INC. UP TO 22,027,780 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(3) Registration No. 333-287699 PROSPECTUS IMUNON, INC. UP TO 22,027,780 SHARES OF COMMON STOCK This prospectus relates to the offer and resale, from time to time, by the selling securityholders named in this prospectus (the “Selling Securityholders”) of up to an aggregate of 22,027,780 shares of common stock, par value $0.01 per share, of Imunon, Inc. (the “Common Sto |
|
| June 13, 2025 |
Offer Letter, dated September 20, 2022, between the Company and Kimberly Graper Exhibit 10.1 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Imunon, Inc. |
|
| June 11, 2025 |
June 11, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Imunon, Inc. Registration Statement on Form S-1 File No. 333-287699 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), Imunon, Inc. (the “Company”) hereby requests that the Securities and Exchange Com |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 IMUNON, INC. |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common stock, pa |
|
| May 30, 2025 |
May 30, 2025 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 IMUNON, INC. |
|
| May 27, 2025 |
Form of Registration Rights Agreement. Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 23, 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, |
|
| May 27, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 27, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 23, 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i |
|
| May 27, 2025 |
Exhibit 99.1 IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J. (May 23, 2025) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunothera |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 IMUNON, INC. |
|
| May 27, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 27, 2025 |
Form of Placement Agent Warrant. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2025 |
Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 RW 1 formrw.htm RW Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 May 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Alan Campbell Re: Imunon, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-286403 Ladies and Gentlemen: On April 4, 2025, Imunon, Inc. (the “Registrant” |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 IMUNON, INC. |
|
| May 20, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 IMUNON, INC. |
|
| May 19, 2025 |
As filed with the Securities and Exchange Commission on May 19, 2025 As filed with the Securities and Exchange Commission on May 19, 2025 Registration No. |
|
| May 19, 2025 |
Form of Common Stock Purchase Warrant. Exhibit 4.9 IMUNON, INC. Warrant To Purchase Common Stock Warrant Shares: [●] Issuance Date: [●], 2025 Initial Exercise Date: [●], 2025 Imunon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, |
|
| May 19, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| May 19, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock, |
|
| May 13, 2025 |
Form of Exchange Agreement, dated May 12, 2025. Exhibit 10.1 Exchange Agreement THIS EXCHANGE AGREEMENT (the “Agreement”) is dated as of May 12, 2025 (the “Effective Date”), by and among Imunon, Inc., a Delaware corporation (the “Company”), and each Holder identified on the signature pages hereto (each, a “Holder” and collectively, the “Holders”). WHEREAS, prior to the execution of this Agreement, the Company entered into that certain Securitie |
|
| May 13, 2025 |
As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No. |
|
| May 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock, |
|
| May 13, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| May 13, 2025 |
Form of Common Stock Purchase Warrant. Exhibit 4.9 IMUNON, INC. Warrant To Purchase Common Stock Warrant Shares: [●] Issuance Date: [●], 2025 Initial Exercise Date: [●], 2025 Imunon, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, |
|
| May 13, 2025 |
Form of Exchange Agreement, dated May 12, 2025. Exhibit 10.31 Exchange Agreement THIS EXCHANGE AGREEMENT (the “Agreement”) is dated as of May 12, 2025 (the “Effective Date”), by and among Imunon, Inc., a Delaware corporation (the “Company”), and each Holder identified on the signature pages hereto (each, a “Holder” and collectively, the “Holders”). WHEREAS, prior to the execution of this Agreement, the Company entered into that certain Securiti |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Imunon, Inc. |
|
| May 13, 2025 |
Form of Placement Agency Agreement. Exhibit 1.1 [], 2025 Imunon, Inc. Attention: Stacy R. Lindborg 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Lindborg: Subject to the terms and conditions of this letter agreement (the “Agreement”) by and between Brookline Capital Markets, a division of Arcadia Securities, LLC, as placement agent (the “Placement Agent”), and Imunon, Inc., a Delaware cor |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I |
|
| May 12, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Imunon, Inc. |
|
| May 12, 2025 |
Exhibit 99.1 IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May |
|
| April 4, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [], 2025, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in th |
|
| April 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity Common stock, |
|
| April 4, 2025 |
Form of Placement Agency Agreement. Exhibit 1.1 [], 2025 Imunon, Inc. Attention: Stacy R. Lindborg 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Lindborg: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as lead placement agent (“A.G.P.”), Brookline Capital Markets, a division of Arcadia Securities, LLC, as a co-placem |
|
| April 4, 2025 |
Exhibit 4.8 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Exercise Date: [], 2025 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| April 4, 2025 |
Form of Common Stock Purchase Warrant. Exhibit 4.9 WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: [] Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No. |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 IMUNON, INC. |
|
| March 24, 2025 |
Exhibit 99.1 IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation of trial sites underway for ground-breaking Phase 3 pivotal trial of DNA-mediated IL-12 therapeutic Company to hold conference call on Tuesd |
|
| March 19, 2025 |
CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC. PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on March 19, 2025 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE C |
|
| February 27, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Imunon, Inc. |
|
| February 27, 2025 |
Exhibit 99.1 IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1 2025 Company to hold conference call t |
|
| February 27, 2025 |
Exhibit 19 |
|
| February 27, 2025 |
Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware |
|
| February 27, 2025 |
EXHIBIT 4.7 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED DESCRIPTION OF CAPITAL STOCK The following summary of the general terms and provisions of the capital stock of Imunon, Inc. (“Imunon”, “we”, “our”) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Amended an |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex |
|
| February 10, 2025 |
Exhibit 99.1 IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunot |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2025 IMUNON, INC. |
|
| February 10, 2025 |
Offer Letter of Employment between Imunon, Inc. and Douglas Faller Exhibit 10.1 |
|
| November 27, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 IMUNON, INC. |
|
| November 14, 2024 |
CLSN / Imunon Inc / Ayrton Capital LLC Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* IMUNON, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 15117N503 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 14, 2024 |
IMNN / Imunon, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm2428264d3sc13ga.htm SC 13G/A CUSIP No: 15117N602 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Imunon, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Sec |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Imunon, Inc. |
|
| November 7, 2024 |
Exhibit 10.5 |
|
| November 7, 2024 |
Conference call today at 11:00 a.m. ET Exhibit 99.1 IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 7, 2024 – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three and nine months ended September 30, 2024. The Company also provide |
|
| October 7, 2024 |
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Exhibit 99.1 IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) LAWRENCEVILLE, N.J. (October 7, 2024) – IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options to purchas |
|
| October 7, 2024 |
Exhibit 10.1 |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 IMUNON, INC. |
|
| September 27, 2024 |
Imunon, Inc. 5,000,000 SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933 in connection with Registration Statement No. |
|
| September 24, 2024 |
September 24, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Imunon, Inc. (the “Company”) Registration Statement Filed on Form S-1 (the “Registration Statement”) File No. 333-281834 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby re |
|
| September 20, 2024 |
As filed with the Securities and Exchange Commission on September 20, 2024 As filed with the Securities and Exchange Commission on September 20, 2024 Registration No. |
|
| September 3, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 IMUNON, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 3, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) $5,500,000 Imunon, Inc. Common Stock We have entered into an At the Market Offering Agreement, dated as of May 25, 2022, as amended by Amendment No. 1 to At the Market Offering Agreement, dated as of May 15, 2024, which, as amended, we refer to as the ATM Agreement, with H.C. Wainw |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024 As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. |
|
| August 29, 2024 |
EX-99.1 4 ex99-1.htm Exhibit 99.1 IMUNON, INC. TERMS AND CONDITIONS OF STOCK OPTION AND RESTRICTED STOCK NONQUALIFIED STOCK OPTION AND RESTRICTED STOCK GRANT AGREEMENT THIS NONQUALIFIED STOCK OPTION AND RESTICTED STOCK GRANT AGREEMENT (this “Agreement”) is made and entered into as of the day of , 202, by and between IMUNON, INC. (the “Corporation”), a Delaware corporation, and , an individual empl |
|
| August 29, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type |
|
| August 29, 2024 |
Calculation of Registration Fee Exhibit 107.1 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per share (“Common Stoc |
|
| August 29, 2024 |
As filed with the Securities and Exchange Commission on August 29, 2024 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on August 29, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMUNON, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 997 Lenox D |
|
| August 14, 2024 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Final AUGUST 12, 2024 IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (August 14, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immuno-oncology therapy, today reported financial results for |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Imunon, Inc. |
|
| August 5, 2024 |
EX-99.I 2 tm2420811d1ex99-i.htm EXHIBIT I CUSIP No: 15117N602 Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. (hereinafter called "the Company"), whose Registered Office is situated at PO Box 309GT, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands. WHEREAS, by agreement dated July 16, 2015, |
|
| August 5, 2024 |
EX-99.II 3 tm2420811d1ex99-ii.htm EXHIBIT II CUSIP No: 15117N602 EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Imunon, Inc., $0.01 par value per share, is bei |
|
| August 5, 2024 |
IMNN / Imunon, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 15117N602 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Imunon, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 15117N602 (CUSIP Number) July 30, |
|
| August 1, 2024 |
Imunon, Inc. 5,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-279425 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2024) Imunon, Inc. 5,000,000 Shares of Common Stock We are offering directly to certain purchasers 5,000,000 shares (the “Shares”) of our common stock, par value $0.01 per share. The Shares are being offered pursuant to a securities purchase agreement, dated as of July 30, 2024 (the “Pur |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 IMUNON, INC. |
|
| July 31, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 31, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| July 31, 2024 |
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Exhibit 99.1 IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules LAWRENCEVILLE, N.J. (July 31, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC. |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 IMUNON, INC. |
|
| July 30, 2024 |
Imunon, Inc. Phase 2 OVATION 2 Data Presentation Exhibit 99.2 |
|
| July 30, 2024 |
Exhibit 99.1 IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 ● Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in the intent-to-treat patient population compared with the standard-of-care control arm ● Overall survi |
|
| June 13, 2024 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 (June 12, 2024) IMUNON, INC. |
|
| May 20, 2024 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as April 15, 2024 (the “Effective Date”), by and between Imunon, Inc. (the “Client”) and Monomoy Advisors, LLC (“Monomoy”). The Client and Monomoy are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” The Parties agree that Monomoy will be engaged on the following |
|
| May 20, 2024 |
Exhibit 10.1 RETIREMENT AND CONSULTING AGREEMENT This Retirement and Consulting Agreement (the “Agreement”) is entered into by and between Jeffrey Church (“Executive”) and Imunon, Inc., a Delaware corporation (the “Company”), effective as of May 17, 2024 (the “Effective Date”). 1. Retirement. (a) Executive has informed the Company of his intent to voluntarily retire on June 1, 2024, or such earlie |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 IMUNON, INC. |
|
| May 20, 2024 |
May 20, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Imunon, Inc. (the “Company”) Registration Statement Filed on Form S-3 (the “Registration Statement”) File No. 333-279425 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfu |
|
| May 15, 2024 |
Exhibit 4.6 CELSION CORPORATION and [NAME OF TRUSTEE], as Trustee INDENTURE Dated as of , 202 CROSS-REFERENCE TABLE TIA Section Indenture Section 310 (a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.10 (b) 7.08; 7.10 (b)(1) 7.10 311 (a) N.A. (b) 7.11 (c) 7.11 312 (a) N.A. (b) 2.06 (c) 10.03 313 (a) 10.03 (b) 7.06 (b)(1) 7.08 (b)(2) N.A. (c) 7.06 (d) 7.06 314 (a) 4.08; 10.04 (b) N.A. (c)(1) |
|
| May 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Carry Forward Form T |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 15, 2024 As filed with the Securities and Exchange Commission on May 15, 2024 Registration No. |
|
| May 15, 2024 |
Exhibit 1.3 May 15, 2024 Imunon, Inc. 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648 Attention: Jeffrey Church, Chief Financial Officer Re: Amendment No. 1 to At The Market Offering Agreement Dear Mr. Church: Reference is made to the At The Market Offering Agreement, dated as of May 25, 2022 (the “ATM Agreement”), between Imunon, Inc. (f/k/a Celsion Corporation) (the “Company”) and H.C. Wainw |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I |
|
| May 13, 2024 |
Exhibit 10.1 SERIAL NUMBER: 2018SOP- IMUNON, INC. 2018 STOCK INCENTIVE PLAN INCENTIVE STOCK OPTION GRANT AGREEMENT THIS GRANT AGREEMENT (this “Agreement”) is made and entered into as of the day of , by and between IMUNON, INC. (the “Corporation”), a Delaware corporation, and , an individual employed by or performing services for the Corporation (“Grantee”). ARTICLE 1 GRANT OF OPTION Section 1.1 Gr |
|
| May 13, 2024 |
Exhibit 10.2 SERIAL NUMBER: 2018RSG- IMUNON, INC 2018 STOCK INCENTIVE PLAN RESTRICTED STOCK AGREEMENT THIS STOCK AGREEMENT (this “Agreement”) is made and entered into as of the day of , by and between IMUNON, INC (the “Corporation”), a Delaware corporation, and , an individual employed by or performing services for the Corporation (“Grantee”). ARTICLE 1 GRANT OF RESTRICTED STOCK Section 1.1 Grant |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Imunon, Inc. |
|
| May 13, 2024 |
Exhibit 99.1 IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (May 13, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the three mont |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 IMUNON, INC. |
|
| May 8, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into effective as of the 3rd day of May, 2024 (the “Effective Date”), by and between Imunon, Inc., a Delaware corporation (the “Company”), and Stacy Lindborg, Ph.D., an individual (the “Executive”). WITNESSETH WHEREAS, the Company desires to retain the Executive to serve in the capacities of President |
|
| May 8, 2024 |
Exhibit 99.1 IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J. (May 8, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-media |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 11, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 (April 10, 2024) Imunon, Inc. |
|
| April 11, 2024 |
IMUNON Reports Compliance with Nasdaq Listing Requirements Exhibit 99.1 IMUNON Reports Compliance with Nasdaq Listing Requirements LAWRENCEVILLE, N.J. (April 11, 2024) – IMUNON, Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Sto |
|
| April 10, 2024 |
Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 April 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Jason Drory Re: Imunon, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-276174 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, |
|
| March 28, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Imunon, Inc. |
|
| March 28, 2024 |
Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex |
|
| March 28, 2024 |
Exhibit 97 Imunon, Inc. Executive Officer Incentive Compensation Recovery Policy I. Purpose The Board of Directors (the “Board”) of Imunon, Inc., a Delaware corporation (the “Company”), has adopted this policy (this “Policy”) which requires the recovery of certain executive compensation in the event that the Company is required to prepare an Accounting Restatement (as defined below). References he |
|
| March 28, 2024 |
Exhibit 99.1 IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 28, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 Imunon, Inc. |
|
| March 18, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF IMUNON, INC. (Compiled and reflecting all amendments through March 15, 2024) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the corporation shall be fixed in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The board of directors (the “Bo |
|
| March 12, 2024 |
Exhibit 99.1 IMUNON Announces Leadership Change Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J. (March 12, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vacci |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Imunon, Inc. |
|
| February 9, 2024 |
Form of Series A Common Stock Purchase Warrant. Exhibit 4.8 SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 2024 THIS SERIES A WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 9, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [•], 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee (3) Carry Forward Fo |
|
| February 9, 2024 |
Form of Series B Common Stock Purchase Warrant. Exhibit 4.9 SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 2024 THIS SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| January 18, 2024 |
Exhibit 4.7 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Exercise Date: [*], 202[●] THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 17, 2024 As filed with the Securities and Exchange Commission on January 17, 2024 Registration No. |
|
| January 18, 2024 |
Form of Placement Agency Agreement Exhibit 1.1 [], 2024 Imunon, Inc. Attention: Dr. Corinne Le Goff 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Re: Placement Agency Agreement Dear Dr. Le Goff: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as lead placement agent (“A.G.P.”), Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline,” |
|
| January 18, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.8 WARRANT TO PURCHASE SHARES OF COMMON STOCK IMUNON, INC. Warrant Shares: Original Issuance Date: [*] , 202[●] THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Origina |
|
| January 18, 2024 |
Form of Securities Purchase Agreement. Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Imunon, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 (December 26, 2023) Imunon, Inc. |
|
| December 20, 2023 |
As filed with the Securities and Exchange Commission on December 20, 2023 As filed with the Securities and Exchange Commission on December 20, 2023 Registration No. |
|
| December 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry-Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee (3) Carry Forward Fo |
|
| December 11, 2023 |
Offer Letter of Employment between Imunon, Inc. and Sébastien Hazard Exhibit 10.1 December 7, 2023 Dr. Sébastien Hazard 7 Rangeley Rd. Winchester, MA 01890 [email protected] Dear Sébastien, I am pleased to extend to you an offer of employment with IMUNON, Inc. as Executive Vice President and Chief Medical Officer. In this capacity, you will be a member of IMUNON’s senior executive staff and will report directly to me. Your starting salary will be $18,269.23 |
|
| December 11, 2023 |
Exhibit 99.1 IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J. (December 11, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on de |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 IMUNON, INC. |
|
| November 14, 2023 |
Exhibit 99.1 IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins Today at 10:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug- |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Imunon, Inc. |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Imunon, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Equity Common Stock Rule 457(c) and Rule 457(h) 1,030,0 |
|
| August 10, 2023 |
Exhibit 99.1 IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (August 10, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development c |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, In |
|
| August 10, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Imunon, Inc. |
|
| June 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 (June 14, 2023) IMUNON, INC. |
|
| June 15, 2023 |
Exhibit 10.1 IMUNON, INC. 2018 STOCK INCENTIVE PLAN, AS AMENDED AS OF JUNE 14, 2023 I. INTRODUCTION 1.1 Purposes. The purposes of the IMUNON, Inc. 2018 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to adva |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 (June 14, 2023) IMUNON, INC. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imunon, I |
|
| May 11, 2023 |
Exhibit 99.1 IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (May 11, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focuse |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Imunon, Inc. |
|
| May 5, 2023 |
Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 May 5, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Vanessa Robertson/Kevin Vaughn Re: Imunon, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 30, 2023 File No. 001-15911 Ladies and Gentlemen: This letter |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO.: 001-15911 IMUNON, INC. (Ex |
|
| March 30, 2023 |
Exhibit 99.1 IMUNON Reports 2022 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 30, 2023) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and |
|
| March 30, 2023 |
Exhibit 21.1 Subsidiaries of Imunon, Inc. Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware Celsion GmbH Switzerland |
|
| March 30, 2023 |
Exhibit 10.25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (“Bank”), and the borrower listed on Schedule I hereto (“Borrower”). The parties agree as follows: 1 LOAN AND TERMS OF PAYMENT 1.1 Term Loan. (a) Availability. Subject to the terms and conditions of this Agreement, upo |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Imunon, Inc. |
|
| March 24, 2023 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF IMUNON, INC. (Compiled and reflecting all amendments through March 22, 2023) Imunon, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Imunon, Inc. 2. The Corporation was originally incorporated |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 (March 22, 2023) Imunon, Inc. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2023 (February 7, 2023) Imunon, Inc. |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 (December 31, 2022) IMUNON, INC. |
|
| November 15, 2022 |
IMUNON, Inc. Third Quarter 2022 Conference Call Monday, November 14, 2022 11:00 a.m. Eastern time Exhibit 99.1 IMUNON, Inc. Third Quarter 2022 Conference Call Monday, November 14, 2022 11:00 a.m. Eastern time Operator Please stand by. Good morning. My name is Marlise and I will be your operator today. At this time, I would like to welcome you to IMUNON?s third quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background noise. Following the speak |
|
| November 15, 2022 |
Imunon, Inc. Corporate Presentation – November 2022 Exhibit 99.2 |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 (November 14, 2022) IMUNON, INC. |
|
| November 14, 2022 |
Exhibit 99.1 IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month period |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Imunon, Inc. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 Imuno |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 (October 3, 2022) IMUNON, INC. |
|
| October 3, 2022 |
Exhibit 99.1 Imunon Appoints James E. Dentzer to its Board of Directors CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J. (October 3, 2022) ? Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug development company, announces the appointment of James E. Dentzer to its Board of Directors, effective immediately. Mr. Dentzer is the chief executive off |
|
| September 19, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF CELSION CORPORATION Celsion Corporation (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of the Corporation is Celsion Corporation. SECOND: The original Certificate of Incorporation of the Corporation (fo |
|
| September 19, 2022 |
Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF IMUNON, INC. (Compiled and reflecting all amendments through September 19, 2022) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the corporation shall be fixed in the Certificate of Incorporation of the corporation, as amended from time to time (the ?Certificate of Incorporation?). 1.2 OTHER OFFICES. The board of directors (the |
|
| September 19, 2022 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 (September 16, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| September 19, 2022 |
Exhibiti 99.1 Celsion Corporation Announces Company Name Change to Imunon, Inc. New name reflects the evolution of the Company?s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., September 19, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of t |
|
| September 19, 2022 |
Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE REDEEMABLE PREFERRED STOCK AND SERIES B CONVERTIBLE REDEEMABLE PREFERRED STOCK OF CELSION CORPORATION Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Celsion Corporation, a corporation organized and existing under the laws of the State of Delaware (the ?Company?), in accordance with the provisions of |
|
| August 15, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION CO |
|
| August 15, 2022 |
As filed with the Securities and Exchange Commission on August 15, 2022 As filed with the Securities and Exchange Commission on August 15, 2022 Registration No. |
|
| August 15, 2022 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 Celsion Corporation (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock Rule 457(c) and Rule 457(h) 513,333 $ 2. |
|
| August 15, 2022 |
Exhibit 99.1 Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (August 15, 2022) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated i |
|
| July 19, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of the 18th day of July 2022 (the ?Effective Date?), by and between Celsion Corporation, a Delaware corporation (the ?Company?), and Michael H. Tardugno, an individual (the ?Executive?). WITNESSETH WHEREAS, the parties hereto previously entered into that certain Amended and Restated |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 (July 18, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| July 19, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into effective as of the 18th day of July 2022 (the ?Effective Date?), by and between Celsion Corporation, a Delaware corporation (the ?Company?), and Corinne Le Goff, an individual (the ?Executive?). WITNESSETH WHEREAS, the Company desires to employ the Executive to serve in the capacity as President |
|
| July 19, 2022 |
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) Exhibit 99.2 Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) LAWRENCEVILLE, N.J., July 19, 2022 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company?s Board of Directors approved the grant of (i) inducement stock options (the ?I |
|
| July 19, 2022 |
Exhibit 99.1 Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company?s Board of Directors has appointed biopharmaceutica |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 (June 13, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 25, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-254515 PROSPECTUS SUPPLEMENT DATED MAY 25, 2022 (To prospectus dated March 30, 2021) Up to $7,500,000 Common Stock We have entered into an At the Market Offering Agreement, dated as of May 25, 2022 (the ?ATM Agreement?) with H.C. Wainwright & Co., LLC (?Wainwright?), relating to shares of our common stock offered by this prospectus supplement a |
|
| May 25, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 25, 2022 |
Exhibit 10.1 CELSION CORPORATION Shares of Common Stock (par value $0.01 per share) At The Market Offering Agreement May 25, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Celsion Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with H.C. Wainwright & Co., LLC (the ?Agent?), as follows: 1. Issuance and Sale of |
|
| May 16, 2022 |
Exhibit 99.1 Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (May 16, 2022) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immun |
|
| May 16, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION C |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| April 8, 2022 |
EX-FILING FEES 2 ex107.htm Exhibit 107 The prospectus supplement to which this Exhibit 107 is attached is a final prospectus for the related offering. The maximum aggregate offering price of such offering is $7,000,000.00. |
|
| April 8, 2022 |
1,328,274 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-254515 PROSPECTUS SUPPLEMENT DATED APRIL 6, 2022 (To prospectus dated March 30, 2021) 1,328,274 Shares of Common Stock We are offering 1,328,274 shares of our common stock, par value $0.01 per share, pursuant to this prospectus supplement and the accompanying prospectus, and securities purchase agreements, at a price of $5.27 per share. Our com |
|
| April 7, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 (April 6, 2022) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| April 7, 2022 |
EX-1.1 2 ex1-1.htm Exhibit 1.1 April 6, 2022 Celsion Corporation 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Attn: Michael H. Tardugno Chairman, President and Chief Executive Officer Dear Mr. Tardugno: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Celsion Corporation, a Delaware corporation (the “Company”), that t |
|
| April 7, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of April 6, 2022, between Celsion Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set |
|
| April 7, 2022 |
Exhibit 99.1 CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES LAWRENCEVILLE, NJ, April 6, 2022 ? Celsion Corporation (NASDAQ: CLSN) (?Celsion? or the ?Company?), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price of $ |
|
| March 31, 2022 |
Subsidiaries of Celsion Corporation Exhibit 21.1 Subsidiaries of Celsion Corporation Name Jurisdiction of Incorporation CLSN Laboratories, Inc. Delaware Celsion GmbH Switzerland |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION CORPO |
|
| March 31, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| March 31, 2022 |
Exhibit 99.1 Celsion Corporation Reports 2021 Financial Results and Provides Business Update Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 31, 2022) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based immunotherapy and next-gene |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2022 (March 15, 2022) Celsion Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-15911 52-1256615 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No. |
|
| March 4, 2022 |
Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2022 (March 3, 2022) Celsion Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-15911 52-1256615 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 (February 24, 2022) Celsion Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-15911 52-1256615 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| February 28, 2022 |
Certificate of Amendment to Certificate of Incorporation of Celsion Corporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF CELSION CORPORATION Celsion Corporation (the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of the Corporation is Celsion Corporation. SECOND: The original Certificate of Incorporation of the Corporation (fo |
|
| February 28, 2022 |
Celsion Corporation Announces Stock Consolidation Exhibit 99.1 Celsion Corporation Announces Stock Consolidation LAWRENCEVILLE, N.J., February 28, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on |
|
| February 14, 2022 |
CLSN / Celsion Corporation / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 15117N503 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Celsion Corporation (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 15117N503 (CUSIP Number) D |
|
| February 11, 2022 |
CLSN / Celsion Corporation / Altium Capital Management LP - AMENDMENT TO SC 13G Passive Investment SC 13G/A 1 clsn-sc13ga123121.htm AMENDMENT TO SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Celsion Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 15117N503 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this St |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| January 14, 2022 |
Exhibit 99.1 Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock LAWRENCEVILLE, N.J., January 13, 2022 ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registered direct offering wit |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2022 Celsion Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-15911 52-1256615 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 12, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-254515 PROSPECTUS SUPPLEMENT DATED January 10, 2022 (To prospectus dated March 30, 2021) 50,000 Shares Series B Convertible Redeemable Preferred Stock 15,000,000 Shares of Common Stock issuable upon conversion of Series B Convertible Redeemable Preferred Stock We are offering 50,000 shares of our Series B Convertible Redeemable Preferred Stock, |
|
| January 12, 2022 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-254515 PROSPECTUS SUPPLEMENT DATED January 10, 2022 (To prospectus dated March 30, 2021) 50,000 Shares Series A Convertible Redeemable Preferred Stock 16,483,516 Shares of Common Stock issuable upon conversion of Series A Convertible Redeemable Preferred Stock We are offering 50,000 shares of our Series A Convertible Redeemable Preferred Stock, |
|
| January 11, 2022 |
Exhibit 99.1 Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock LAWRENCEVILLE, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that it has entered into a securities purchase agreement |
|
| January 11, 2022 |
Exhibit 3.1 celsion corporation CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES a CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Jeffrey W. Church, does hereby certify that: 1. He is the Executive Vice President and CFO of Celsion Corporation, a Delaware corporation (the ?Corporation?). 2. The Corp |
|
| January 11, 2022 |
Exhibit 1.1 January 10, 2022 Celsion Corporation 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 Attn: Michael H. Tardugno Chairman, President and Chief Executive Officer Dear Mr. Tardugno: This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent?) and Celsion Corporation, a Delaware corporation (the ?Company?), that the Placement Age |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Celsion Corporation (Exact Name of Registrant as Specified in Charter) Delaware 001-15911 52-1256615 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 11, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of January 10, 2022, between Celsion Corporation, a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions s |
|
| January 11, 2022 |
Exhibit 3.2 celsion corporation CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B CONVERTIBLE REDEEMABLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, Jeffrey W. Church, does hereby certify that: 1. He is the Executive Vice President and CFO of Celsion Corporation, a Delaware corporation (the ?Corporation?). 2. The Corp |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2021 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| December 10, 2021 |
Amended and Restated Bylaws of Celsion Corporation, dated December 7, 2021 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF CELSION CORPORATION (Compiled and reflecting all amendments through December 7, 2021) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of the corporation shall be fixed in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). 1.2 OTHER OFFICES. The board of directors |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 (December 7, 2021) CELSION CORPORATION (Exact name of Registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| December 3, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2021 (December 2, 2021) CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| November 15, 2021 |
Exhibit 99.1 Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (November 15, 2021) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based immunothe |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSI |
|
| November 15, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| November 15, 2021 |
EXHIBIT 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?). The parties agree as follows: 1 LOAN AND TERMS OF PAYMENT 1.1 Term Loan. (a) Availability. Subject to the terms and conditions of this Agreement, upon |
|
| August 12, 2021 |
Exhibit 99.1 Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (August 12, 2021) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-based |
|
| August 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 CELSION CORPORATION (Exact name of registrant as specified in its Charter) Delaware 001-15911 52-1256615 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-15911 CELSION CO |
|
| June 21, 2021 |
Exhibit 99.1 Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital LAWRENCEVILLE, N.J. (June 21, 2021) ? Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-g |
